Your session is about to expire
← Back to Search
Transcranial Photobiomodulation for Alzheimer's Disease
Study Summary
This trial will study the effects of t-PBM, a pulsed, 808nm wavelength laser delivery to the forehead, on amnestic Mild Cognitive Impairment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- A family member had dementia before turning 60.I have mild memory loss that affects my daily life, but I am not severely impaired.I have no significant abnormal lab results or physical exam findings.You are afraid of small spaces or have metal objects in your body that would prevent you from having an MRI scan.I have not used any light-activated drugs in the last 14 days.I do not have a history of serious brain conditions or other types of dementia besides Alzheimer's.I do not have any unstable health conditions.I have serious skin issues on my scalp where a procedure is planned.You have a current diagnosis of alcohol or drug addiction or a major mental illness such as schizophrenia, bipolar disorder, PTSD, or depression.I am not on any medication that affects my thinking, except for stable use of memantine or acetylcholinesterase inhibitors for over 6 months.I have had a heart attack or stroke.I am between 65 and 85 years old.
- Group 1: Sham
- Group 2: Transcranial Photobiomodulation (t-PBM)
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Who can sign up to be part of this research project?
"This study is looking for 125 participants with Alzheimer disease aged 65 and 85. Candidates are required to meet the following criteria: Age ≥ 65 years and ≤ 85 years, Meets the Petersen MCI criteria for Amnestic MCI (single and multiple domain) with a Clinical Dementia Rating (CDR) between 0.5 to 1, and a Functional Assessment Staging (FAST) of 1-3, Consents to permit and identifies a willing informed relative, family member, or spouse for study staff to interview to confirm subject reports as per UDS 3.0 guidelines., Have at least a high school"
How many people are signing up for this clinical trial?
"That is accurate. The clinical trial was originally posted on 4/27/2021, and as of right now, they are still recruiting participants. They are looking for a total of 125 people at 3 different sites."
How can interested individuals sign up for this research project?
"The study, which was originally advertised on clinicaltrials.gov on April 27th 2021, is still recruiting patients."
Could you explain the age requirements for this clinical trial?
"The age requirements to participate in this trial are being 65 years or older, and younger than 85 years old."
Has 18F-MK-6240 received the go-ahead from the FDA?
"There is some evidence that 18F-MK-6240 is safe, but none to support its efficacy. Our team rates it as a 2."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- NYU Langone Health: < 24 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger